BTX-1188 (HPK1 inhibitor)
Advanced Solid Tumors
Phase 1Active (Partnered with BioNTech)
Key Facts
Indication
Advanced Solid Tumors
Phase
Phase 1
Status
Active (Partnered with BioNTech)
Company
About Ryvu Therapeutics
Ryvu Therapeutics is a Polish public company advancing a portfolio of targeted oncology therapies, with its lead programs in clinical trials. The company leverages a proprietary drug discovery platform to identify and develop small molecule inhibitors against novel targets like STING and HPK1. Its strategy combines internal R&D with strategic partnerships to advance its pipeline and create value. As a clinical-stage firm, it is pre-revenue and funded through equity offerings and collaborations.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |
| BI-1808 | BioInvent International | Phase 1/2a |
| GIGA-564 | GigaGen | Phase 1 |
| Venadaparib (IDX-1197) | Idience | Phase 1a |
| VET3-TGI | KaliVir Immunotherapeutics | Phase 1 |
| IT-141 (Etoposide IVECT™) | Intezyne | Phase 1 |
| NC318 | NextCure | Phase 1/2 |
| VisAcT (18F-AraG) Imaging in Solid Tumors | CellSight Technologies | Phase 1/2 |